[HTML][HTML] Antifibrotics and reduced mortality in idiopathic pulmonary fibrosis: immortal time bias

S Suissa, K Suissa - American Journal of Respiratory and Critical …, 2023 - atsjournals.org
1. Khor YH, Ng Y, Barnes H, Goh NSL, McDonald CF, Holland AE. Prognosis of idiopathic
pulmonary fibrosis without anti-fibrotic therapy: a systematic review. Eur Respir Rev 2020; …

[HTML][HTML] Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias

S Suissa, K Suissa - American Journal of Respiratory and Critical …, 2023 - ncbi.nlm.nih.gov
1. Khor YH, Ng Y, Barnes H, Goh NSL, McDonald CF, Holland AE. Prognosis of idiopathic
pulmonary fibrosis without anti-fibrotic therapy: a systematic review. Eur Respir Rev 2020; …

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias.

S Suissa, K Suissa - … Journal of Respiratory & Critical Care …, 2023 - search.ebscohost.com
The article offers information on a review of observational studies examining the effect of
antifibrotics on mortality in idiopathic pulmonary fibrosis. Topics covered include studies with …

[PDF][PDF] Austin ILD Registry and CARE-PF Investigators: Deborah Assayag

CJ Ryerson - Respir Med, 2021 - pdfs.semanticscholar.org
1. Khor YH, Ng Y, Barnes H, Goh NSL, McDonald CF, Holland AE. Prognosis of idiopathic
pulmonary fibrosis without anti-fibrotic therapy: a systematic review. Eur Respir Rev 2020; …

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias.

S Suissa, K Suissa - American Journal of Respiratory and Critical …, 2023 - europepmc.org
1. Khor YH, Ng Y, Barnes H, Goh NSL, McDonald CF, Holland AE. Prognosis of idiopathic
pulmonary fibrosis without anti-fibrotic therapy: a systematic review. Eur Respir Rev 2020; …

[引用][C] Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias

S Suissa, K Suissa - American journal of respiratory and …, 2023 - pubmed.ncbi.nlm.nih.gov